1371535-86-2

Upstream product

• 1227923-29-6 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1227923-94-5 6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)benzo[h]quinazolin-4(3H)-one 
• 4919-43-1 1-amino-2-naphthoic acid 
• 1227924-42-6 1-amino-4-bromo-2-naphthoic acid 
• 1227924-43-7 1-amino-4-bromo-N-[(1S,2S)-2-hydroxycyclohexyl]-2-naphthamide 
• 1227924-44-8 6-bromo-3-[(1S,2S)-2-hydroxycyclohexyl]benzo[h]quinazolin-4(3H)-one 
• 352530-36-0 ((6-chloropyridin-3-yl)methyl)zinc(II) chloride 
• 5158-46-3 methylzinc chloride 
• 881-03-8 1-nitro-2-methylnaphthalene 
• 339015-80-4 Dimethyl-[(E)-2-(1-nitro-naphthalen-2-yl)-vinyl]-amine 
• 103987-83-3 1-nitro-2-naphthoic acid 
• 594-27-4 tetramethylstannane 
• 931-15-7 (1S,2S)-trans-2-aminocyclohexanol 

Downstream Products

• 1371535-87-3 3-((1S,2S)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-6-((6-methylpyridin-3-yl)methyl)-2,3-dihydrobenzo[h]quinazolin-4(1H)-one 

Relevant academic research and scientific papers

DIHYDROPYRIDO QUINAZOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

Disclosed herein are compounds of formula (I), which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases, in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

PROCESS FOR MAKING M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.

DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease